The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...
U-scan: The health gadget that wants to analyse your pee An NFL kicker just hit a 68-yard field goal. Yes, you read that ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.
Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in ...
A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...
We wish to point out some major issues with Abdel-Fattah and colleagues’ FUTURE study.1 Surprisingly, substantial key information is not found in the main text, but in the supplementary appendix of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback